Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes
Effect of a Six-Week Mindfulness-Based Intervention on Glycemic Control, Cardiovascular Autonomic Function, Anxiety, and Depression in Adults With Type 2 Diabetes: A Randomized Controlled Trial
The goal of this clinical trial was to learn whether a six-week mindfulness program, added to standard diabetes treatment, improves blood sugar control, heart rate variability (a measure of how the nervous system regulates the heart), anxiety, and depression in adults aged 18 to 60 years with type 2 diabetes. The main questions it aimed to answer were:
- Does the mindfulness program lower glycated hemoglobin (HbA1c), fasting blood glucose, and 2-hour postprandial blood glucose?
- Does it improve heart rate variability, cardiovascular autonomic dysfunction status, and anxiety and depression scores?
Researchers compared participants who received standard therapy plus the mindfulness program with participants who received standard therapy alone.
Participants in the mindfulness group listened to weekly audio-guided practices sent through WhatsApp (mindful eating, breathing exercise, body scan, mindful walking, dealing with unpleasant experiences, and loving-kindness meditation) and were asked to practice daily for six weeks. All participants had blood tests, a 3-minute heart rate variability recording, and the Hospital Anxiety and Depression Scale questionnaire at the start of the study and after six weeks.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This single-center, parallel-group randomized controlled trial with a pretest-posttest design was conducted at the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital, Surakarta, Indonesia, from March to June 2025. Adults with type 2 diabetes receiving antidiabetic treatment were randomly allocated in a 1:1 ratio to standard therapy plus a six-week mindfulness program (intervention) or standard therapy alone (control).
The mindfulness program was adapted from a mindfulness-based stress reduction (MBSR) handbook and consisted of one theme per week: mindful eating, breathing exercise, body scan, staying present (mindful walking), dealing with unpleasant experiences, and loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants were asked to practice daily (approximately 20 minutes per day) and received regular reminders.
Outcomes were assessed at baseline and after six weeks. HbA1c was measured with a point-of-care analyzer (Afinion HbA1c, Abbott); fasting and 2-hour postprandial venous blood glucose were measured with an enzymatic photometric method in the hospital laboratory. Short-term heart rate variability was recorded for 3 minutes with a fingertip photoplethysmographic sensor (SA-3000P, Medicore), and cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. Anxiety and depression were assessed with the Indonesian version of the Hospital Anxiety and Depression Scale.
The sample size (13 per group, increased to 14 per group to allow for 10% attrition; 28 in total) was calculated with OpenEpi (two-sided alpha 0.05, power 80%). Between-group comparisons used the independent t-test or Mann-Whitney U test, within-group comparisons used the paired t-test or Wilcoxon signed-rank test, and changes in autonomic dysfunction status were analyzed with the McNemar test.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Central Java
-
Surakarta, Central Java, Indonésia, 57126
- Dr. Moewardi General Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults aged 18-60 years with type 2 diabetes mellitus
- Receiving antidiabetic treatment
- Attending the Internal Medicine Outpatient Clinic of Dr. Moewardi General Hospital
- Willing to participate and provided written informed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Thyroid disorders
- Cardiac arrhythmia
- Use of drugs that may affect heart rate variability (e.g., beta-blockers, antidepressants, antipsychotics, or anxiolytics)
- Coffee consumption within 1 week before the start of the study
- Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Mindfulness plus standard therapy
Participants continued their standard antidiabetic therapy and completed a six-week audio-guided mindfulness program delivered through WhatsApp. |
A six-week mindfulness program adapted from a mindfulness-based stress reduction (MBSR) handbook, with one theme per week: (1) mindful eating, (2) breathing exercise, (3) body scan, (4) staying present - mindful walking, (5) dealing with unpleasant experiences, and (6) loving-kindness meditation. Guided practices were delivered weekly as audio recordings through WhatsApp; participants practiced daily (approximately 20 minutes per day) and received regular reminders, in addition to standard antidiabetic therapy.
Outros nomes:
|
|
Sem intervenção: Standard therapy
Participants continued their standard antidiabetic therapy without the mindfulness program. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in glycated hemoglobin (HbA1c)
Prazo: Baseline and 6 weeks
|
HbA1c (%) measured with a point-of-care analyzer (Afinion HbA1c, Abbott). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in fasting blood glucose
Prazo: Baseline and 6 weeks
|
Venous blood glucose after an 8-10-hour fast, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in 2-hour postprandial blood glucose
Prazo: Baseline and 6 weeks
|
Venous blood glucose 2 hours after a meal, measured with an enzymatic photometric method (mg/dL). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in standard deviation of normal-to-normal intervals (SDNN)
Prazo: Baseline and 6 weeks
|
Short-term heart rate variability (ms) from a 3-minute recording with a fingertip photoplethysmographic sensor (SA-3000P, Medicore). Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Number of participants with cardiovascular autonomic dysfunction
Prazo: Baseline and 6 weeks
|
Cardiovascular autonomic dysfunction was defined as three or more heart rate variability indices deviating by more than 2.5 standard deviations from the device reference values. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) score
Prazo: Baseline and 6 weeks
|
HADS anxiety subscale, range 0-21; higher scores indicate more severe anxiety symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
|
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) score
Prazo: Baseline and 6 weeks
|
HADS depression subscale, range 0-21; higher scores indicate more severe depressive symptoms. Change was calculated as the 6-week value minus the baseline value. |
Baseline and 6 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Farha Naily Fawzia, MD, Universitas Sebelas Maret
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Doenças Neuromusculares
- Doenças Metabólicas
- Sintomas Comportamentais
- Doenças do Sistema Nervoso Periférico
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Complicações do Diabetes
- Comportamento
- Doenças Nutricionais e Metabólicas
- Transtornos de ansiedade
- Diabetes Mellitus, Tipo 2
- Depressão
- Neuropatias diabéticas
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2.765/XII/HREC/2024
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be made publicly available to protect participant privacy; de-identified data may be obtained from the principal investigator upon reasonable request.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .